Volume 25, Issue 2 - Medical Communication

Staying ahead of the game in the changing arena of ethical medical communications - Viewpoint of a freelance medical writer

Author: Sharon Smalley

Abstract

Download the full article

References

1. International Federation of Pharmaceutical Manufacturers & Associations. IFPMA Code of Practice. 2012 [cited 2016 Feb]. Available from: http://www.ifpma.org/wp-content/ uploads/2016/01/IFPMA_Code_of_ Practice_2012_new_logo.pdf
2. European Federation of Pharma - ceutical Industries and Associations. EFPIA Code on the Promotion of Prescription-only Medicines to, and Interactions with, Healthcare Professionals. 2014 Jun 06 [cited 2016 Feb]. Available from: http://transparency.efpia.eu/uploads/ Modules/Documents/efpia-hcp-code- 2014.pdf
3. European Federation of Pharma - ceutical Industries and Associations. EFPIA HCP/HCO Disclosure Code. Consolidated Version 2014. 2014 Jun 6 [cited 2016 Feb]. Available from: http:// transparency.efpia.eu/uploads/ Modules/Documents/efpiadisclosure- code-2014.pdf.
4. Pharmaceutical Research and Manufacturers of America (PhRMA). Code on Interactions with Healthcare Professionals. Updated 2009 Jan [cited 2016 Feb]. Available from: http://www.phrma.org/sites/default/ files/pdf/phrma_marketing_code_ 2008.pdf
5. Association of the British Pharmaceutical Industry: Code of Practice for the Pharmaceutical Industry 2016 together with the Prescription Medicines Code of Practice Authority. 2016 Jan 01 [cited 2016 Feb]. Available from: http://transparency.efpia.eu/countries /download/27/document/code-ofpractice- 2016.pdf
6. UK Bribery Act 2010. 2010 Apr 08 [cited 2016 Feb]. Available from: http://www.legislation.gov.uk/ukpga/ 2010/23/contents
7. Foreign Corrupt Practices Act. Updated November 2012 [cited 2016 Feb]. Available from: http://www. justice.gov/sites/default/files/criminal -fraud/legacy/2015/01/16/guide.pdf
8. Francer J, Izquierdo JZ, Music T, Narsai K, Nikidis C, Simmonds H, et al. Ethical pharmaceutical promotion and communications worldwide: codes and regulations. Philos Ethics Humanit Med. 2014;9:7.
9. International Committee of Medical Journal Editors (ICMJE). Recommend ations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. Updated 2015 Dec [cited 2016 Feb]. Available from: http://www.icmje.org/ icmje-recommendations.pdf
10. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good publication practice for commun cating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461–4.
11. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Ann Intern Med. 2010;152(11):726–32.
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8): 573–7.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
14. Hamilton CW, Gertel A, Jacobs A, Marchington J, Weaver S, Woolley K. Mythbusting medical writing: goodbye, ghosts! hello, help! Account Res. 2016;23(3):178–94.
15. Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, et al. Professional medical writing support and the quality of randomised controlled trial reporting: a crosssectional study. BMJ Open. 2016;6(2):e010329.